Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19322704 | 1.00 | LPAR1 (0.41) | LPAR1LPAR3MEN1CYP3A4KMT2A | |
| SCHEMBL18511792 | 0.98 | LPAR1 (0.40) | LPAR1LPAR3MEN1CYP3A4KMT2A | |
| SCHEMBL18874442 | 0.98 | LPAR1 (0.40) | LPAR1LPAR3MEN1CYP3A4KMT2A | |
| SCHEMBL18512361 | 0.97 | LPAR1 (0.40) | LPAR1LPAR3MEN1CYP3A4KMT2A | |
| SCHEMBL18512392 | 0.97 | LPAR1 (0.40) | LPAR1LPAR3MEN1CYP3A4KMT2A | |
| SCHEMBL22268704 | 0.94 | CETP (0.40) | LPAR1LPAR3MEN1CYP3A4KMT2A | |
| SCHEMBL22268812 | 0.91 | MEN1 (0.41) | MEN1CYP3A4KMT2A | |
| SCHEMBL18503208 | 0.90 | LPAR1 (0.36) | LPAR1LPAR3MEN1CYP3A4KMT2A | |
| SCHEMBL22268742 | 0.90 | LPAR1 (0.36) | LPAR1LPAR3MEN1CYP3A4KMT2A | |
| SCHEMBL18503165 | 0.90 | LPAR1 (0.36) | LPAR1LPAR3MEN1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253628-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253628-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, PNP, DPYD | LPAR1 1584/4885LPAR3 2779/4885MEN1 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.